Friday, April 15, 2011

WhisprWave Small Craft Intrusion Barrier and Vessel Exclusion Barrier Products designated as Qualified Anti-Terrorism Technologies

SUMMIT , N.J. - April 15, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Wave Dispersion Technologies, Inc. reports the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT). Wave Dispersion Technologies, the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of Homeland Security (DHS) SAFETY Act Designation.
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation," said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology," said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Tech Stock News; Investor Ideas adds New Cloud Computing Stock, GBS
Enterprises, Inc. (OTCBB: GBSX) to List of Cloud Stocks

POINT ROBERTS, Wash., April 15 2011 - www.InvestorIdeas.com, a leader
in sector stock research adds cloud computing stock, GBS Enterprises, Inc.
(OTCBB: GBSX) as a featured company on the site and its recently created
directory of cloud computing stocks.

GBS Enterprises, Inc. (OTCBB:GBSX) is the parent company of Group
Business Software (GBS) which provides a portfolio of Cloud Computing
software technologies and Application Services to address the needs of private
enterprises, Data Center providers, ISV's, OEM's as well as government
organizations. GBS caters primarily to mid-market and enterprise B2B size
organizations. GBS has over 3,500 customers in thirty-eight countries spanning
four continents, representing more than 5,000,000 active users of its products.

Recent News:

GBS Enterprises (OTCBB:GBSX) Acquires PAVONE AG, a Leading Provider of Business
Process Management Technologies for the IBM Lotus Platforms

FRANKFURT, Germany - April 14, 2011 (Investorideas.com cloud computing stocks newswire) – GBS
Enterprises, Inc. (OTCBB:GBSX) announced today the acquisition of PAVONE AG, a leader in business
process management and optimization technologies. PAVONE's extensive workflow software for Lotus
Notes and Domino along with their large customer base is well suited to GBS Enterprises portfolio strategy.
This acquisition of PAVONE complements GBS's majority ownership in Group Business Software (GBS),
and further strengthens their leading industry position on the IBM Lotus Platforms and expands their cloud
computing technology offerings beyond the IBM Lotus market.

Full news : http://www.investorideas.com/CO/GBS/news/2011/04141.asp

Visit the GBSX company profile on Investorideas.com

Visit the Cloud computing stocks directory at Investorideas.com

http://www.investorideas.com/TSS/Cloud_Computing_Stocks.asp

Request news and info on GBSX

Company Contact:
Gary MacDonald
EVP and Chief Corporate Development Officer
GBS Enterprises, Incorporated
+1.917.477.9509
gmacdonald@gbsx.us

Sign up for the free investor news letter and get stock alerts in leading
sectors!

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include;
cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks,
water, tech, defense stocks, nanotech, agriculture and gaming.

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no
guarantees as to the accuracy of information presented. All Information relating to featured companies is
sourced from public documents and/ or the company and is not the opinion of our web sites. This site is
currently compensated by featured companies, news submissions and online advertising.

Disclosure: GBS Enterprises, Inc. (OTCBB: GBSX) is a paid showcase tech stock, cloud computing stock on
Investorideas.com (April 2011 - 1500 per month by third party)

www.InvestorIdeas.com/About/Disclaimer.asp

Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary
companies. These forward-looking statements are often identified by the use of forward-looking terminology such
as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and
uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed,
estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only
as of the date of this press release. The Company's actual results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors.

www.Investorideas.com
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com

Source – Investorideas.com
Investor Ideas announces 1st quarter performance of 32% for its Solar Stocks Portfolio

Point Roberts, South Salem, New York –April 15, 2011 - Investorideas.com, a leader in sector stock
research including renewable energy stocks, reports on 1st quarter performance of 32% for its Solar
Portfolio, created by solar contributor J. Peter Lynch.

Investor Ideas solar portfolio was UP 32% for the first quarter of 2011 vs the general markets increase of
5.3%. This outperformance follows the solar portfolio's full year 2010 performance of +43% verses the
general markets increase of 13%, this is especially impressive in light of the fact that the balance of the
stocks in the solar sector were DOWN an average of 14% in 2010. In addition, the 2010 performance was
accomplished with no turnover (zero trades) made in 2010.

Follow Solar Stocks Commentary with J Peter Lynch

Read his articles and commentary on solar stocks
http://www.investorideas.com/PL/

Read the technical review and portfolio of solar stocks

http://www.investorideas.com/PL/Solar-Stocks-Review.asp

Mr. Lynch has worked, for 33 years as a Wall Street security analyst, an independent security analyst
and private investor in small emerging technology companies. He has been actively involved in following
developments in the renewable energy sector since 1977 and is regarded as an expert in this field. He
was the contributing editor for 17 years to the Photovoltaic Insider Report, an early publication in PV
that was directed at industrial subscribers, such as major energy companies, utilities and governments
around the world. He is currently a private investor and has from time to time been a financial/technology
consultant to a number of companies. He can be reached via e-mail at: SOLARJPL@aol.com. Please
visit his website for the promotion of solar energy – www.sunseries.net.
Subscribe to the Peter Lynch solar RSS feed; http://www.investorideas.com/RSS/feeds/PL.xml
Disclaimer: The views and opinions expressed in the research published are those of the individual
companies and writers and not necessarily those of Investorideas.com® or any of the industry sector
portals. At the time of publication, writers may hold positions in the stocks or companies mentioned.

Research other solar with the renewable energy stocks directory; a global stock

directory featuring over 1100 green stocks. Investors also have the option to access the directory
as part of the Investor Ideas Membership premium content that currently features an additional
10 stock directories, including the water stocks directory and all cleantech stock directories. http://
www.investorideas.com/membership/

About InvestorIdeas.com:InvestorIdeas.com is a leader in investor stock research by sector. Sectors

we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks,
energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

About Investor Ideas Green Investor content: Visit our showcase green stocks and research green
stocks at: www.renewableenergystocks.com and http://www.investorideas.com/GI/

Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and

links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.

Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy
of information presented. All Information relating to featured companies is sourced from public documents and/ or the company
and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and
online advertising. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/
Clientspecifics.asp

For more information contact:

Dawn Van Zant 800.665.0411, Email: dvanzant@investorideas.com or Cali at
cvanzant@investorideas.com

Source: www.Investorideas.com

Thursday, April 14, 2011

Green Car Stocks Trading Alert; Investors Rush into Green IPO for Zipcar (NASDAQ: ZIP)

Point Roberts, WA - April 14 , 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in sector stock research including the green and renewable energy sector reports on trading for newly listed green rental car company Zipcar (NASDAQ: ZIP). The stock’s IPO debut gains investor interest in the sector again as it trades at $28.25 up 10.25 (56.94%), trading as high as $31.50.
Investorideas.com Green Newswire Zipcar sold 6,666,667 shares of common stock and certain selling stockholders are offering 3,017,442 shares of common stock. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,452,617 shares at the initial public offering price.
Zipcar intends to use the net proceeds from this offering for repayment of certain debt, business expansion, working capital and other general corporate purposes, including the development of new services, sales and marketing activities and capital expenditures. Zipcar will not receive any proceeds from the sale of shares by the selling stockholders.
Green Car Company Snapshots
Zipcar (NASDAQ: ZIP). Zipcar is the world's leading car sharing network with more than 560,000 members and over 8,000 vehicles in urban areas and college campuses throughout the United States, Canada and the United Kingdom. Zipcar offers more than 30 makes and models of self-service vehicles by the hour or day to residents and businesses looking for an alternative to the high costs and hassles of owning a car.
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles
Visit the showcase page at Investorideas.com
http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 11 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Research more info on green stocks:
http://www.investorideas.com/gi/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
To become a showcase company, contact us below.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com
'Natural gas stocks and Natural gas companies' most searched by Investors on Investorideas.com as Oil Prices Spiked
Natural Gas Stocks Directory Updated for April

POINT ROBERTS, Wash. - April 14, 2011 - www.InvestorIdeas.com, a leader in sector stock research, updates the natural gas stocks directory for April 2011. Natural gas stocks and natural gas companies have been the top searched phrases and content on Investorideas.com recently. As oil prices spiked. Investors looked at natural gas stocks as clean, cost effective energy solutions.
Investorideas.com covers leading sectors for investors with research tools including stock directories, news, articles and featured stocks within each sector.
Sectors covered include oil and gas, natural gas, defense, biotech, mining, nanotech, water, tech, agriculture and other high profile sectors.
Natural gas stocks directory preview:
The complete natural gas stocks directory is part of the Investorideas.com member’s login content of 12 stock directories including oil and gas stocks and renewable energy stocks directory.
3D Oil Limited (ASX.TSO.AX) engages in the production and development of upstream oil and gas properties in Australia. It holds a 100% interest in the Gippsland Basin exploration permit Vic/P57 covering an area of 750 square kilometers located in offshore Victoria; and the Bass Basin exploration permit T41-P covering approximately 2,805 square kilometers located in Tasmania.
Abraxas Petroleum Corporation ( NasdaqCM:AXAS) is a San Antonio based crude oil and natural gas exploration and production company with operations across the Rocky Mountain, Mid-Continent, Permian Basin and onshore Gulf Coast regions of the United States and in the province of Alberta, Canada.
Abu Dhabi National Energy Company PJSC (ADX:TAQA.AE) is a global energy company with operations in power generation, water desalination, upstream oil/gas, pipelines and gas storage. In addition to supplying more than 98% of power in its domestic market, TAQA is expanding its footprint across the Middle East, The Americas and Europe. It is one of the largest companies listed on the ADX.
ACTIVENERGY INCOME TRUST UNITS (AEU-UN.TO) is a TSX listed closed-end investment fund that invests in a diversified portfolio of energy companies with an emphasis on oil and gas as well as common shares of Canadian and U.S.-based issuers operating in the energy sector.
Adams Resources And Energy (AMEX:AE) together with its subsidiaries, engages in marketing crude oil, natural gas, and petroleum products. It purchases crude oil, and arranges sales and deliveries to refiners and other customers in Texas and Louisiana with additional operations in Michigan and New Mexico; purchases, distributes, and markets natural gas; and offers value added services by providing access to common carrier pipelines and handling daily volume balancing requirements, as well as risk management services. The company also markets branded and unbranded refined petroleum products, such as motor fuels comprising automotive gasoline, biodiesel, and conventional diesel fuel; and lubricants consisting of passenger car motor oils, and industrial oils and greases. In addition, it involves in railroad servicing industry by fueling and lubricating locomotives, as well as performing routine maintenance on the power units; and operates as a direct-to-vessel marine fuel and lube vendor primarily in Texas Gulf Coast and southern Louisiana. Further, the company transports liquid chemicals on a ‘for hire’ basis in the continental United States and Canada, as well as engages in the exploration and development of domestic oil and natural gas properties primarily in Texas and the south central region of the United States.
Adelaide Energy Limited (ASX:ADE.AX) is focused on oil and gas exploration in the Cooper and Otway Basins of South Australia. .
Admiral Bay Resources Inc (TSX:ADB.V) is an unconventional gas production company focused on the development of projects in the Cherokee Basin in southeast Kansas and the Appalachian Basin in Pennsylvania.
Advance Energy Limited (ASX.AVD.AX) is focused on the acquisition and development of oil and gas producing assets in Texas USA. The company aims to acquire assets with a combination of debt and equity that have current production and cash flow and to enhance production and cash flow through the further development of these assets. Once a property has reached its full productive potential and/or has achieved economic payout to Advance Energy, the Company looks to on sell all or part of its interest. It is the aim of the Company to develop a portfolio of assets which will be developed and traded to maximise returns on funds invested.
Advantage Energy Income Fund (TSX:AVN-UN.TO; NYSE:AAV) is a conventional oil and gas royalty trust that acquires and develops reserves in Western Canada. The Trust’s head office is located in Calgary, Alberta, Canada. Growth has been achieved through a series of corporate and property acquisitions combined with an active drilling program, which has increased production from 7,300 boe/d at inception in 2001 to approximately 30,000 to 34,000 boe/d in 2009. From inception through December 2008 the Trust’s reserve life index has increased from 7.2 years to 15.2 years.
AGL Resources (NYSE:AGL) an Atlanta-based energy services company, serves approximately 2.3 million customers in six states. The company also owns Houston-based Sequent Energy Management, an asset manager serving natural gas wholesale customers throughout North America. As a 70 percent owner in the SouthStar partnership, AGL Resources markets natural gas to consumers in Georgia under the Georgia Natural Gas brand. The company also owns and operates Jefferson Island Storage & Hub, a high-deliverability natural gas storage facility near the Henry Hub in Louisiana.
Visit the natural gas stocks directory : http://www.investorideas.com/Companies/NaturalGas/Stock_List.asp
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector investing content.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com

Cloud Computing Stock News; GBS Enterprises (OTCBB:GBSX) Acquires PAVONE AG, a Leading Provider of Business Process Management Technologies for the IBM Lotus Platforms

FRANKFURT, Germany - April 14, 2011 (Investorideas.com cloud computing stocks newswire) � GBS Enterprises, Inc. (OTCBB:GBSX) announced today the acquisition of PAVONE AG, a leader in business process management and optimization technologies. PAVONE's extensive workflow software for Lotus Notes and Domino along with their large customer base is well suited to GBS Enterprises portfolio strategy. This acquisition of PAVONE complements GBS's majority ownership in Group Business Software (GBS), and further strengthens their leading industry position on the IBM Lotus Platforms and expands their cloud computing technology offerings beyond the IBM Lotus market.
"By joining the family of GBS Enterprise companies allows our customers a broader range of support and technology options in North America and Europe," says Professor Ludwig Nastansky, PhD, Chairman of the Board of PAVONE AG. "This will allow us to increase our R&D investment in areas of cloud computing, mobility, email and CRM management, and analytics."
In his comments Joerg Ott, Chairman and CEO of GBS Enterprises, said that: "PAVONE is a strong and well timed addition to GBS. This acquisition brings us technology, a synergistic customer base and more than 40 employees spanning engineering, sales and services. PAVONE provides GBS with an excellent workflow technology to incorporate into our Lotus offerings, plus PAVONE Live is a workflow engine that can be utilized beyond the Lotus market as a cloud based solution on demand which is ideal for GBS's cloud technology offerings." Joerg also mentioned that "GBS will be able to extend its footprint in banking and insurance and have access to a new supplier vertical. In addition to their great software and extensive customer base, we get great people with the specific skills sets we need to drive the company forward." Ott noted too that GBS Experts, the consulting services group at GBS, will now be able to leverage the workflow engine in any of their custom development engagements.
PAVONE currently has offices in Germany and the UK. They have over 2,500 customers and over 150,000 users worldwide. Some of their customers include Deutsche Bundes Bank, BMW, Linde AG, Philips, British Sugar and Mahle Industries.
About GBS Enterprises, Inc.
GBS Enterprises, Inc. is the parent company of Group Business Software (GBS) which provides a portfolio of Cloud Computing software technologies and Application Services to address the needs of private enterprises, Data Center providers, ISV's, OEM's as well as government organizations. GBS caters primarily to mid-market and enterprise B2B size organizations. GBS has over 3,500 customers in thirty-eight countries spanning four continents, representing more than 5,000,000 active users of its products.
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors.
Contact:
Gary MacDonald
EVP and Chief Corporate Development Officer
GBS Enterprises, Incorporated
+1.917.477.9509
gmacdonald@gbsx.us
Disclosure: GBS Enterprises, Inc. (OTCBB:GBSX) is a paid showcase tech stock, cloud computing stock on Investorideas.com (April 2011 - 1500 per month by third party)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Electric Car Stocks Trading Alert; EVCARCO, Inc. (OTCBB: EVCA) Sets Into Motion an Aggressive Dealership Acquisition Plan for 2011

FT. WORTH, TX � April 14, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) (Pinksheets:EVCA) is pioneering a new way to meet the demands of 21st century car buyers. In its latest broad approach, EVCA has set into motion a dealership acquisition program aimed at increasing both corporate presence and overall net value of the corporation in respect to sales and inventory.
Scott O'Neal, COO and Co-Founder of EVCARCO, stated, "Our acquisition plan is to evaluate and acquire dealerships and align the Company with major manufacturers that produce vehicles consumers want to drive. We feel the dealerships that are currently on the market today give EVCARCO the opportunity to build value and move forward in the direction of profitability."
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. EVCARCO -- Future Driven®
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
Visit the EVCA showcase profile at Investorideas.com
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Homeland Defense News; Wave Dispersion Technologies, Inc. Achieves U.S. Department of Homeland Security SAFETY Act Designation
WhisprWave Floating Security Barriers Designated as a Qualified Anti-Terrorism Technology

SUMMIT, N.J. - April 14, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Wave Dispersion Technologies, Inc. (WDT) the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of Homeland Security (DHS) SAFETY Act Designation, and the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT).
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation,” said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology,” said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
>Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High
Biodefense Stocks Sector Snapshot; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX ), (NasdaqGM: SIGA)

Point Roberts, WA - April 14, 2011 - Investorideas.com, a leader in sector stock research including biotech and biodefense stocks issues a trading alert on Emergent Biosolutions, Inc. (NYSE: EBS) as it hit a 52 week high in Wednesday’s trading. The Company reported its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress.
Biotech/ Biodefense Stocks Sector Snapshot ( as of close April 14 th)
  • Aethlon Medical (OTCBB: AEMD) closed at $0.1036 on over 242,000 shares, with its 52 week range of $0.096 - 0.35
  • Dynasil Corporation (NASDAQ GM: DYSL) ended at $4.14, with a 52 week range of $ 2.35 - 7.48
  • Emergent Biosolutions, Inc. (NYSE: EBS ) closed at $24,68 hitting its 52 week high; $14.11 - 25.24
  • PharmAthene, Inc. (NYSE Amex: PIP) finished trading at $3.17, its 52 week range of $1.25 - 4.96
  • Protalix BioTherapeutics, Inc. (AMEX: PLX ) closed at $7.24, up 0.15 (2.12%)
  • Siga Technologies (NasdaqGM: SIGA ) ended trading at $13.4, up 0.48 (3.71%) on over 437,000 shares
Recent News:
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
ROCKVILLE, Md.--- Emergent BioSolutions Inc. (NYSE: EBS ) announced that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals and companies in the global vaccine industry.
"This award is a testament to the collective efforts of the Emergent BioSolutions team, who on a daily basis and all over the world, lives out the corporate mission – to protect life,” said Mr. El-Hibri. "Our team shares a passion and commitment to make vital contributions to address unmet and underserved medical needs. It is an honor to be recognized for the work that we do.”
In selecting the winner for this category, the distinguished panel of judges evaluated the finalists based on their commitment to disease prevention and treatment, leadership, contribution to company performance, communication, and vision, industry influence, and achievements in company positioning and status.
Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation
SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.
Full news: http://www.investorideas.com/CO/AEMD/news/2011/04121.asp
Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD),
Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Visit the Aethlon Medical (OTCBB: AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Emergent Biosolutions, Inc. (NYSE: EBS )
Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. www.emergentbiosolutions.com

About www.InvestorIdeas.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Research Biotech Stocks atInvestorideas.com
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011     
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
A Broad-Spectrum Treatment Strategy to Address HIV, Hepatitis-C (HCV) and other Infectious Disease Conditions; Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce

Point Roberts, WA. - April 14, 2011 � Investorideas.com, a leader in sector stock research presents a new interview in its series of biotech Q&A's, featuring Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD).
The Hemopurifier® from Aethlon Medical is a first-in-class medical device candidate to treat infectious disease. Human studies have documented that the Hemopurifier® can significantly reduce viral load in Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients in the absence of antiviral drugs. A study is currently underway to demonstrate the benefit of the Hemopurifier® as an adjunct to HCV drug therapy. Additional details can be accessed online at www.aethlonmedical.com
Q&A Interview
InvestorIdeas: How does your Hemopurifier® differ from drug therapies to treat infectious disease?
Mr. Joyce: Well, our approach is a complete departure from the consensus approach of introducing drug agents into the body to inhibit viral replication. As you are likely aware, these agents can have countering side effects or mechanisms of action that may not be fully understood. So, instead of adding agents into the body, our Hemopurifier® subtracts or removes viruses and other harmful particles from circulation without drug-related side effects. We think our therapeutic filtration approach could redefine the premise of how to treat infectious disease and we believe our strategy is far more innovative than another me-too drug inhibitor.
InvestorIdeas: Is a device that removes harmful particles from the body really considered to be innovative?
Mr. Joyce: The idea of a therapeutic filtration device that can remove harmful particles from circulation is not original. The basis of kidney dialysis, which keeps individuals with renal disease alive, is based on therapeutic filtration. However, like dialysis, previous therapeutic filtration strategies have sought to remove particles from circulation by molecule size, which is an indiscriminate approach that can also remove elements from circulation that are required for health. This factor has primarily limited the use of therapeutic filtration to niche markets. Our Hemopurifier® is truly innovative in the sense that we discriminate to selectively remove infectious viruses and other harmful particles from the entire circulatory system. It is this advancement that allows us to pursue opportunities in the much larger infectious disease and cancer markets.
InvestorIdeas: So it would seem your Hemopurifier® is positioned as a competitor to drug therapies.
Mr. Joyce: That is certainly not our intent. In fact, we expect to be an ally to the drug industry for several compelling reasons. First, if you really want to enhance or extend the benefit of drug therapies, you remove the strains of viruses that are causing drugs to fail and you do it without adding drug toxicity or interaction risks. But to fully unlock the capability of drug therapies you need to provide other complementary mechanisms that are beyond the reach of drugs. In that regard, we provide a strategy to address the toxins shed from viral surfaces to kill immune cells and particles known as exosomes that allow viruses to transport other disease-enhancing particles below the surveillance of the immune system. So our device in combination with drug therapy would seem to be a win-win scenario.
InvestorIdeas: What if a virus is not treatable with drug therapy?
Mr. Joyce: In reality, a vast majority of the viruses that are known to be infectious to man are not treatable with drugs. In scenarios that are life threatening, our Hemopurifer® is likely to be the sole strategy to address viral infections that are not treatable with drugs. For this reason, our Hemopurifier® is immensely valuable as new viruses like the coronavirus underlying the SARS outbreak of 2003 will emerge naturally in the future. We also face the looming threat of biological weapons purposely designed to defeat drug therapies. In either case, our Hemopurifier® provides a decision free first response that can augment the body's own immune response to such exposures, which is certainly more logical than an post-exposure strategy comprised of first identifying the virus that is killing people, and then establishing post-death research programs that may or may not yield a viable treatment candidate years after the fact.
InvestorIdeas: Thank you.
About Aethlon Medical ( OTCBB: AEMD )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011       
800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Teva New Drug Application (NDA) for Testosterone Gel, Bio-T-Gel™
New Drug Application (NDA) Accepted for filing by FDA

LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) reports a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.
Bio-T-Gel is a testosterone gel for the treatment of male hypogonadism or low testosterone levels. Bio-T-Gel was developed initially by BioSante, and then it was licensed to Teva for late stage clinical development. Teva is responsible for all Bio-T-Gel regulatory and marketing activities. BioSante will receive certain milestone payments and royalties upon commercialization. The current U.S. market for male testosterone products is over $1.2 billion.
"We are extremely excited by Teva's NDA filing of Bio-T-Gel," said Stephen M. Simes, BioSante's president & CEO. "We are confident that Teva has the expertise and resources to capture significant market share once Bio-T-Gel is launched. We look forward to receiving milestone payments and royalties on Bio-T-Gel after approval and launch."
About Male Hypogonadism
Typically, a man's testosterone level is considered low if it's below a level of approximately 300 ng/dL. Low testosterone can be caused by a signaling problem that occurs between the brain and the testes that causes the production of testosterone to drop below normal. Low testosterone also can occur when the body can't make normal levels of testosterone and can lead to a medical condition known as hypogonadism that has many symptoms including fatigue, decreased energy, reduced sexual desire and depressed mood.
It is estimated that low testosterone affects more than 4 to 5 million men in the U.S. Common symptoms include reduced sex drive, decreased energy, loss of body hair or reduced shaving, and depressed mood. There is no cure for hypogonadism. It is a medical condition that usually requires ongoing treatment.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Wednesday, April 13, 2011

Gaming Stocks Sector Close-Up; Investors Betting on Gaming Stocks See Gains; (NYQ: LVS), (NYQ: MGM), (NMS: PENN), (NMS: WYNN)

POINT ROBERTS, WA - April 13, 2011 - InvestorIdeas.com is a leader in investor stock research by sector, releases a sector snapshot on gaming stocks for April 13, 2011.
The Wall Street Journal reported M G M MIRAGE (NYQ: MGM) * “ said it reached an agreement with Macau mogul Pansy Ho that will give the U.S. casino operator a majority stake in its Chinese joint venture after the venture's planned initial public offering. A date hasn't yet been set for the offering but is expected in May. The IPO could raise around US$1 billion, a person familiar with the situation said earlier this month.” MGM (NYQ: MGM) was up over 6.8% in morning trading.
Gaming Stocks Sector Snapshot
  • International Game Technology (NYSE: IGT ) trading at $15.8, up 0.49 (3.19%) 10:55AM EDT
  • Isle of Capri Casinos, Inc. (NMS: ISLE) trading at $9.06, up 0.06 (0.67%) 10:44AM EDT
  • LAS VEGAS SANDS CORP (NYQ: LVS) trading at 44.83 1.37 (3.15%) 11:02AM EDT
  • M G M MIRAGE (NYQ: MGM) trading at $13.47, up 0.86 (6.82%) 10:50AM EDT
  • Penn National Gaming, Inc (NMS: PENN) trading at $37.09, up 0.35 (0.95%) 11:00AM EDT
  • Shuffle Master, Inc.(NasdaqGS: SHFL ) trading at $10.70, up 0.01 (0.09%) 10:52AM EDT
  • Wynn Resorts, Limited (NMS: WYNN) trading at $135.32, up 5.18 (3.98%) 10:49AM EDT
For a directory of gaming stocks visit:
http://www.gamingindustrystocks.com/GIS/Stock_List.asp
Market Snapshot
  • Dow 12,304.56 +40.98 +0.33%
  • Nasdaq 2,768.35 +23.56 +0.86%
  • S&P 500 1,318.28 +4.12 +0.31%
  • 10 Yr Bond(%) 3.52% +0.02
  • Oil 107.16 +0.91 +0.86%
  • Gold 1,457.80 +4.90 +0.34%
* http://online.wsj.com/article/SB10001424052748703730104576260582978118002.html?mod=yahoo_hs
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About our Gaming Portal:
www.GamingIndustryStocks.com, a portal within the InvestorIdeas.com® content umbrella, does not make recommendations, but features industry and stock news, exclusive articles and financial columnists, audio interviews and Podcasts, investor conferences, Blogs, and a directory of stocks in the sector.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com, GamingIndustryStocks.com
Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Teva New Drug Application for Bio-T-Gel™

LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.
Bio-T-Gel is a testosterone gel for the treatment of male hypogonadism or low testosterone levels. Bio-T-Gel was developed initially by BioSante, and then it was licensed to Teva for late stage clinical development. Teva is responsible for all Bio-T-Gel regulatory and marketing activities. BioSante will receive certain milestone payments and royalties upon commercialization. The current U.S. market for male testosterone products is over $1.2 billion.
"We are extremely excited by Teva's NDA filing of Bio-T-Gel," said Stephen M. Simes, BioSante's president & CEO. "We are confident that Teva has the expertise and resources to capture significant market share once Bio-T-Gel is launched. We look forward to receiving milestone payments and royalties on Bio-T-Gel after approval and launch."
About Male Hypogonadism
Typically, a man's testosterone level is considered low if it's below a level of approximately 300 ng/dL. Low testosterone can be caused by a signaling problem that occurs between the brain and the testes that causes the production of testosterone to drop below normal. Low testosterone also can occur when the body can't make normal levels of testosterone and can lead to a medical condition known as hypogonadism that has many symptoms including fatigue, decreased energy, reduced sexual desire and depressed mood.
It is estimated that low testosterone affects more than 4 to 5 million men in the U.S. Common symptoms include reduced sex drive, decreased energy, loss of body hair or reduced shaving, and depressed mood. There is no cure for hypogonadism. It is a medical condition that usually requires ongoing treatment.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).